FibreTuff
Develops FibreTuff PAPC, a biocompatible composite for 3D printing bone-like scaffolds and models with 200-micron pore sizes.
- CEO / Founder
- Robert Joyce
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- $500K
- Latest Round
- Grant
- Key Investors
- Center of Innovative Food Technology (CIFT)
Technology & Products
Key Products
FibreTuff PAPC; PAPC+Nylon66
Technological Advantage
Claimed bone-like performance (ductility, strength, collagen adhesion) and verified 200-micron pore sizes for scaffolds.
Differentiation
Value Proposition
Provides biocompatible materials with bone-like properties (absorbency, hardness, radiopacity) for surgical evaluation and scaffolds, mimicking natural bone performance.
How They Differentiate
Niche focus on lightweight, sustainable, biocompatible materials specifically mimicking bone structure and performance.
Market & Competition
Target Customers
Medical professionals and orthopedic surgeons
Industry Verticals
Medical
Competitors
Oxford Performance Materials (OPM), Evonik (Medical Device Division), Solvay (Specialty Polymers).
Growth & Milestones
Growth Metrics
Bone scaffolds with 200 micron pores; drilled femur models showing robust strength/ductility.
Major Milestones
Evolved from molding/extrusion to 3D printing provider; 2024 conference presentations (SPE FOAMS, Advanced Manufacturing Minneapolis, AMI Polyamides); Rapid+TCT 2025 Detroit presentation; Building M/L platform for 3D printing
Notable Customers
US Department of Defense (DOD), Marshall University.